Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Eczema Atopic Dermatitis Clear all
Terminated No phase listed Observational

Dupilumab Phase 4 Study

NCT03411837
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
12 Years and older
Enrollment
46 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 23, 2026, 2:19 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

NCT03351777
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PR022
Drug
Lead sponsor
Realm Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Jul 23, 2026, 2:19 PM EDT
Not listed No phase listed Observational

Hand Sanitizer Effects on the Skin Barrier

NCT04525521
View directory record Official record
Conditions
Dermatitis Hand, Skin Abnormalities, Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
Hand sanitizer and hand washing
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

NCT01652885
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Fremont, California • San Diego, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

NCT01678092
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
omalizumab
Biological
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

NCT05277571
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
UCB1381, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
16
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

NCT06447506
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Fountain Valley, California • Pompano Beach, Florida • Fayetteville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

NCT05938478
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Tralokinumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 23, 2026, 2:19 PM EDT
Terminated Not applicable Interventional

A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema

NCT01826630
View directory record Official record
Conditions
Eczema, Hand Eczema, Atopic Dermatitis
Interventions
CLn BodyWash, Cetaphil Daily Facial Cleanser
Other
Lead sponsor
Shari L Hand
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gahanna, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

NCT03725722
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • Encino, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

NCT03826901
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
delgocitinib
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
2 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

NCT05906628
View directory record Official record
Conditions
Hand Eczema
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Phoenix, Arizona • Fountain Valley, California • Huntington Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 23, 2026, 2:19 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

NCT07487831
View directory record Official record
Conditions
Atopic Dermatitis (Eczema), Psoriasis
Interventions
Sodium chloride tablets, Placebo Tablets
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

NCT06998056
View directory record Official record
Conditions
Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
3 Months to 2 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

NCT03139981
View directory record Official record
Conditions
Dermatitis, Atopic, Dermatitis Eczema, Dermatitis, Eczematous
Interventions
ASN002, Placebo Oral Tablet
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
9
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 23, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Jul 23, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

NCT04173442
View directory record Official record
Conditions
Atopic Dermatitis (AD), Asthma
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

NCT03568331
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tempe, Arizona • Encino, California + 60 more
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Jul 23, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
BFB759, Placebo
Biological · Drug
Lead sponsor
Bluefin Biomedicine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Encino, California • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 23, 2026, 2:19 PM EDT
Active, not recruiting No phase listed Observational

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

NCT03428646
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
93
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
60
States / cities
Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 23, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
43
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

NCT00703573
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S-777469 400 mg, S-777469 800 mg, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Jul 23, 2026, 2:19 PM EDT